Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

WHIPPANY, N.J.--(BUSINESS WIRE)--The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone1, were presented today as a Late-Breaking Science Session at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC) in Lisbon. Finerenone is marketed as Kerendia® and approved for the treatment of adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in more.

Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes and/or Heart Failure Shared at Heart Failure 2024 Congress

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, the ongoing randomized, double-blind, placebo-controlled, multicenter, event-driven Phase III study is investigating the efficacy (including CV death and total HF events) and safety of finerenone compared to placebo in patients suffering from symptomatic HF with.

Bayer to Present Investigational Data from Comprehensive KERENDIA® (finerenone) Clinical Trial Program at Heart Failure 2024 Congress

WASHINGTON--(BUSINESS WIRE)--WomenHeart: The National Coalition for Women with Heart Disease, in collaboration with Bayer, is proud to announce the launch of the Understanding Her Heart: Women and Cardiovascular Disease initiative. This groundbreaking partnership aims to bolster awareness of heart disease risk factors among women, enhance accessibility to vital heart health information and resources, and mobilize women leaders to champion heart health education in their local communities and na.

WomenHeart and Bayer Join Forces to Enhance Heart Health Awareness and Education Among Women Across the U.S.

BERLIN--(BUSINESS WIRE)--Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting. ACOG takes place from May 17 – 19, in San Francisco, CA, United States. Additional presentations will feature new findings from Bayer's intrauterine systems (IUS) and menopaus.

Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause

CHICAGO--(BUSINESS WIRE)--Leading real-time supply chain visibility provider FourKites today announced that it will join Bayer and Graphic Packaging International in two separate tracks at the upcoming Gartner Supply Chain Symposium/Xpo™ 2024, where the world's chief supply chain officers (CSCOs), experts and supply chain leaders meet to share insights and strategies that can drive tangible impact in their organizations. FourKites founder and CEO Mathew Elenjickal will join Bayer's Global Direc.

FourKites, Bayer and Graphic Packaging International to Present at Gartner Supply Chain Symposium/Xpo 2024

Evotec SE

BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY BERLIN AND HAMBURG, GERMANY / ACCESSWIRE / April 30, 2024 / Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs). The collaboration aims to identify and validate novel targets, with the goal of building a portfolio of precision cardiology therapeutics by leveraging Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs).

Bayer and Evotec Collaborate to Advance Precision Cardiology

Bayer CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare and agriculture group, defying a challenge from one German fund managing house.

Bayer CEO wins first AGM shareholder vote

Bayer shareholder Deka Investment said on Friday it would not join other large investors in supporting the healthcare and agriculture group's management at its annual general meeting.

Bayer investor Deka takes a stand against CEO in annual vote

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues.

Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues

Bayer on Monday confirmed its full-year guidance for earnings and cash flow despite slow business at its crop science and consumer health divisions.

Bayer confirms outlook despite slow businesses in agriculture, consumer health

Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.

Bayer's patent for blood thinner Xarelto invalid, UK court rules

LAS VEGAS--(BUSINESS WIRE)--Bayer and Google Cloud today announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will further develop its innovation platform to accelerate the development and deployment of AI-powered healthcare applications with a clear focus on radiology, using Google Cloud's technology, including its generative AI (gen AI) tools. The collaboration a.

Bayer and Google Cloud to accelerate development of AI-powered healthcare applications for radiologists

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer. Avivi will succeed Jeff Jarrett, who is retiring from the company at the end of May. “I'm pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for n.

Bayer's Consumer Health Division Announces Changes to North America Leadership Team

Alphabet

Google Cloud and Bayer are building a new AI-powered platform to help radiologists work more efficiently.

Google partners with Bayer on new AI product for radiologists

A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Friday it is appealing.

Judge slashes Bayer $1.56 billion Roundup verdict to $611 million

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach.

Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Sue Ann Pentecost as the new Vice President, Head of Pharmaceuticals Communications in the United States. She will report directly to Beth Roden, Senior Vice President, Head of Communications for Bayer U.S., and Head of Communications Bayer Consumer Health NA. Pentecost succeeds Lori Moore, who is retiring at the end of May. Pentecost joined Bayer in 2022 as Head, External Communications for U.S. Pharmaceuticals responsible for above brand.

Bayer Appoints Sue Ann Pentecost as Vice President, Head of U.S. Pharmaceutical Communications

AstraZeneca

Bicycle Therapeutics Plc - ADR

Bristol-Myers

Exelixis

Fusion Pharmaceuticals

Eli Lilly

Merck

Novartis

Takeda Pharmaceutical

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

2 More Potential Biotech Buyout Targets

Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti-blood-clotting therapy.

Bayer says 2024 sales of prostate cancer drug above $1 bln

Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.

Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study

Thermo Fisher Scientific

BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. The CDx will be developed using Thermo Fisher's Oncomine Dx Express Test* on the Ion Torrent Genexus Dx Sy.

Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines

BERLIN--(BUSINESS WIRE)--Bayer's Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused. The company has been making important strides in strengthening its development portfolio and extending its capabilities through collaborations and acquisitions into breakthrough therapeutic fields such as gene therapies and cell therapies. As a next step, Bayer's Pharmaceutical Division is focusing on ren.

Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth

BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. The CDx will be developed using Thermo Fisher's Oncomine Dx Express Test* on the Ion Torrent Genexus Dx System*, a fully i.

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo. In this study, elinzanetant successfully met the primary endpoint demonstrating statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 12 compared to placebo. The long-term safety profile observed.

News for Bayer AG Stock (BAYRY)